Boehringer Ingelheim has acquired Nerio Therapeutics Inc. for a total of up to $1.3 billion. It aims to develop Nerio’s innovative preclinical program as a potential key centerpiece component for its immuno-oncology portfolio. Nerio’s small molecules inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which act as immune checkpoints. Through this mechanism, PTPN1/2 inhibition can activate the immune system to fight cancer cells. Boehringer Ingelheim is committed ...